Trizzino John
SEC CIK 1468534 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVAX | NOVAVAX INC | Pres, COO | 68.1K | — | $10.29M | 38 | 2021-09-13 | 2025-03-07 |
Most active insiders at NVAX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Draghia-Akli Ruxandra | Section 16 | — | — |
| 2 | O'Hara Elaine | EVP, Chief Strategy Off | — | — |
| 3 | Shiver John W. | Dir | — | — |
| 4 | Newton Charles W. | Dir | — | — |
| 5 | Jacobs John C | Pres, CEO, Dir | — | — |
| 6 | King Rachel K. | Dir | — | — |
| 7 | Kelly James Patrick | EVP, CFO, Treas | — | — |
| 8 | Casey Mark J | EVP, CLO | — | — |
| 9 | Alton Gregg H | Dir | — | — |
| 10 | Rodgers Richard J | Dir | — | — |
Trizzino John made no open-market trades at NVAX in the last 12 months.
Transactions 38
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-11 | 2025-03-07 | NVAX | NOVAVAX INC | Trizzino John | Pres, COO | F - Tax | $8.34 | -14.0K | 68.1K | -17% | -$116.4K |
| D | 2025-03-11 | 2025-03-07 | NVAX | NOVAVAX INC | Trizzino John | Pres, COO | M - OptEx | $0.00 | +28.9K | 82.0K | +54% | $0 |
| D | 2025-03-04 | 2025-03-01 | NVAX | NOVAVAX INC | Trizzino John | Pres, COO | M - OptEx | $0.00 | +48.0K | 76.3K | +170% | $0 |
| D | 2025-03-04 | 2025-03-01 | NVAX | NOVAVAX INC | Trizzino John | Pres, COO | F - Tax | $8.33 | -23.2K | 53.1K | -30% | -$193.1K |
| D | 2024-08-21 | 2024-08-19 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $13.90 | -317 | 28.3K | -1% | -$4,406 |
| D | 2024-08-21 | 2024-08-19 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | $0.00 | +655 | 28.6K | +2% | $0 |
| D | 2024-03-12 | 2024-03-10 | NVAX | NOVAVAX INC | Trizzino John | Pres, COO | M - OptEx | — | +4,608 | 30.2K | +18% | — |
| D | 2024-03-12 | 2024-03-10 | NVAX | NOVAVAX INC | Trizzino John | Pres, COO | F - Tax | $5.45 | -2,226 | 28.0K | -7% | -$12.1K |
| D | 2024-03-11 | 2024-03-07 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $5.61 | -14.0K | 25.6K | -35% | -$78.3K |
| D | 2024-03-11 | 2024-03-07 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +28.9K | 39.5K | +271% | — |
| D | 2023-12-18 | 2023-12-14 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $5.69 | -773 | 10.7K | -7% | -$4,398 |
| D | 2023-12-18 | 2023-12-14 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +1,600 | 11.4K | +16% | — |
| D | 2023-08-22 | 2023-08-19 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $7.14 | -317 | 9,828 | -3% | -$2,263 |
| D | 2023-08-22 | 2023-08-19 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +655 | 10.1K | +7% | — |
| D | 2023-06-27 | 2023-06-25 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $6.70 | -403 | 9,490 | -4% | -$2,700 |
| D | 2023-06-27 | 2023-06-25 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +833 | 9,893 | +9% | — |
| D | 2023-03-14 | 2023-03-10 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $6.52 | -2,471 | 9,060 | -21% | -$16.1K |
| D | 2023-03-14 | 2023-03-10 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | $6.52 | +4,609 | 11.5K | +67% | +$30.1K |
| D | 2022-12-16 | 2022-12-14 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $17.23 | -773 | 6,922 | -10% | -$13.3K |
| D | 2022-12-16 | 2022-12-14 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +1,600 | 7,695 | +26% | — |
| D | 2022-09-28 | 2022-09-26 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +3,538 | 7,804 | +83% | — |
| D | 2022-09-28 | 2022-09-26 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $18.87 | -1,709 | 6,095 | -22% | -$32.2K |
| D | 2022-08-23 | 2022-08-19 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $36.22 | -317 | 4,266 | -7% | -$11.5K |
| D | 2022-08-23 | 2022-08-19 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +655 | 4,583 | +17% | — |
| D | 2022-06-28 | 2022-06-25 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +833 | 4,206 | +25% | — |
| D | 2022-06-28 | 2022-06-25 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $51.67 | -278 | 3,928 | -7% | -$14.4K |
| D | 2021-12-16 | 2021-12-14 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $168.43 | -773 | 3,373 | -19% | -$130.2K |
| D | 2021-12-16 | 2021-12-14 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +1,600 | 4,146 | +63% | — |
| DM | 2021-09-29 | 2021-09-28 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | S - Sale+OE | $209.92 | -7,501 | 3,477 | -68% | -$1.57M |
| D | 2021-09-29 | 2021-09-28 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | $19.08 | +7,501 | 10.0K | +295% | +$143.1K |
| DM | 2021-09-29 | 2021-09-27 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | S - Sale+OE | $234.61 | -7,501 | 2,546 | -75% | -$1.76M |
| D | 2021-09-29 | 2021-09-27 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | $19.08 | +7,501 | 10.0K | +295% | +$143.1K |
| D | 2021-09-28 | 2021-09-26 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | — | +3,537 | 4,255 | +493% | — |
| D | 2021-09-28 | 2021-09-26 | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | F - Tax | $248.16 | -1,709 | 2,546 | -40% | -$424.1K |
| DM | 2021-09-22 | 2021-09-20+ | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | S - Sale+OE | $227.47 | -15.0K | 718 | -95% | -$3.41M |
| DM | 2021-09-22 | 2021-09-20+ | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | $19.08 | +15.0K | 8,218 | New | +$286.2K |
| DM | 2021-09-15 | 2021-09-13+ | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | S - Sale+OE | $235.95 | -15.0K | 3,511 | -81% | -$3.54M |
| DM | 2021-09-15 | 2021-09-13+ | NVAX | NOVAVAX INC | Trizzino John | EVP, CCO, CBO | M - OptEx | $19.08 | +15.0K | 8,217 | New | +$286.2K |
Purchase Sale Sale after option exercise All abbreviations